IGF-1 DES (1mg)

What is IGF-1 DES?

IGF-1 DES, also called Des(1-3) IGF-I, is a truncated IGF-1 research analog lacking the first three amino acids of mature IGF-1. This catalog lists a 1mg research vial.

Listed vial contents: 1mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

Which identity should I verify?

Verify the Des(1-3) truncation, expected intact mass and supplied quantity in an original matching lot document. Do not treat evidence for IGF-1 LR3 or native IGF-1 as direct evidence for this construct.

What mechanisms are being studied?

Des(1-3) IGF-I has lower affinity for several IGF-binding proteins than native IGF-I. Researchers use that distinction to investigate how binding proteins regulate receptor exposure and biological responses. It is a different construct from IGF-1 LR3.

What are the research questions?

• IGF-binding-protein interactions
• IGF-receptor responses in cell and animal models
• Construct-matched comparisons with native IGF-1 and IGF-1 LR3

What does the published work describe?

Ballard and colleagues reviewed the biochemical and biological properties of Des(1-3) IGF-I. A later animal study compared IGF analogs that bind poorly to binding proteins. These findings support construct-specific research questions, not a universal potency multiplier or a treatment claim for this vial.

Experimental models in the cited papers

• Biochemical and biological literature review
• Pig and marmoset: comparative IGF-analog study

What could future research explore?

Matched assays could compare native IGF-1, Des(1-3) IGF-I and long-R3 IGF-I while controlling concentration, binding proteins and receptor system. Analytical identity should be established before interpreting those comparisons.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

Review and animal evidence do not verify this inventory or establish human effectiveness or safety. The page does not claim a fixed ten-fold potency, localized action or a specific half-life because those statements vary by model and are not lot evidence.

Study references

1. Ballard FJ, et al. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996. PMID 8930132
2. Tomas FM, et al. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997. PMID 9415072

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.